Table 3. Univariate and multivariate analysis of prognostic factors of overall survival in the training cohort.
Variable | Univariate analysis |
Multivariate analysis |
|||
---|---|---|---|---|---|
Hazard ratio (95% CI) | P | Hazard ratio (95% CI) | P | ||
Age (<70/≥70) | 0.64 (0.25-2.2) | 0.43 | 0.48 (0.17-1.69) | 0.22 | |
Sex (female/male) | 0.18 (0.029-0.58) | 0.0019 | 0.20 (0.032-0.66) | 0.0053 | |
Histologic subtype (epithelioid/others) | 0.44 (0.21-0.99) | 0.048 | 0.75 (0.35-1.77) | 0.49 | |
Pathological stage (I-II/III-IV) | 0.26 (0.042-0.86) | 0.025 | 0.51 (0.24-1.15) | 0.10 | |
Treatment (trimodality/no trimodality) | 0.86 (0.46-1.7) | 0.65 | |||
Hemoglobin (g/L) (<15.6/≥15.6) | 1.81 (0.71-6.1) | 0.23 | |||
WBC count (×109/L) (<5.7/≥5.7) | 0.23 (0.055-0.64) | 0.0028 | |||
Neutrophil count (×109/L) (<3.9/≥3.9) | 0.40 (0.16-0.86) | 0.018 | |||
Lymphocyte count (×109/L) (<1.0/≥1.0) | 2.26 (0.94-4.9) | 0.068 | |||
Platelet count (×109/L) (<350/≥350) | 0.38 (0.20-0.74) | 0.005 | |||
NLR (<3.5/≥3.5) | 0.51 (0.27-0.97) | 0.041 | |||
PLR (<215/≥215) | 0.49 (0.26-0.93) | 0.030 | 0.50 (0.24-0.99) | 0.049 |
WBC, white blood cell; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio.